Pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone as first-line therapy for multiple myeloma

Clinical Lymphoma

Volumn 4, Issue SUPPL. 1, 2003, Pages

  Hussein, Mohamad ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Cardiac toxicity; Hand foot syndrome; Microvessel density; Myelosuppression; VAD regimen

Indexed keywords

DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; PYRIDOXINE; VINCRISTINE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER STAGING; CARDIOTOXICITY; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DEHYDRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; FATIGUE; FEVER; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; POLYNEUROPATHY; PROGNOSIS; SEPSIS; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

EID: 0142029058     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2003.s.004     Document Type: Article

References (20)

1. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin 2003; 53:5-26.
2. Kyle RA. Management of patients with multiple myeloma: emphasizing the role of high-dose therapy. Clin Lymphoma 2001; 2:21-28.
3. Northfelt DW, Martin FJ, Working P, et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol 1996; 36:55-63.
4. Speth PA, van Hoesel QG, Haanen C. Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet 1988; 15:15-31.
5. Alberts DS, Garcia DJ. Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs 1997; 54(suppl 4):30-35.
6. 2. Ann Oncol 2000; 11:1029-1033.
7. Gabizon AA. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 2001; 19:424-436.
8. Rajkumar SV, Leong T, Roche PC, et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 2000; 6:3111-3116.
9. Ribatti D, Vacca A, Nico B, et al. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. Br J Cancer 1999; 79:451-455.
10. Vacca A, Ribatti D, Roncali L, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994; 87:503-508.
11. Chen YH, Feng XX, Schilder L. Effect of vincristine, adriamycin and glucocorticoids on myeloma cells in vitro. Acta Haematol 1993; 89:61-69.
12. Barlogie B, Drewinko B, Benjamin RS, et al. Kinetic response of human lymphoid cells to adriamycin-DNA complex in vitro. Cancer Res 1976; 36:2540-2544.
13. Dingeldein G, Hoffmann M, Huebner G, et al. Phase I/II study with liposomal-encapsulated doxorubicin in VAD- protocol for patients mit multiple myeloma. Blood 2001; 98(suppl):308b (Abstract #4985).
14. Dimopoulos M, Pouli A, Zervas V, et al. Prospective randomized comparison of VAD administered as intravenous bolus injection and of VAD with liposomal doxorubicin (Doxil) as first line treatment in multiple myeloma. Blood 2001; 98(suppl):165a (Abstract #695).
15. Gautier M, Petros W, Peterson B, et al. Doxil, vincristine and dexamethasone: a new regimen for elderly patients with multiple myeloma. Proc Am Soc Clin Oncol 1999; 18:28a (Abstract #101).
16. Tsiara SN, Kapsali E, Christou L, et al. Administration of a modified chemotherapeutic regimen containing vincristine, liposomal doxorubicin and dexamethasone to multiple myeloma patients: preliminary data. Eur J Haematol 2000; 65:118-122.
17. Hussein MA, Wood L, Hsi E, et al. A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients. Cancer 2002; 95:2160-2168.
18. Hussein M, Tonda M, George S, et al. A phase III randomized trial of doxil, vincristine and dexamethasone (DVd) versus vincristine, adriamycin and reduced-dose dexamethasone (VAd) in the treatment of patients with newly diagnosed multiple myeloma (n-MM). Proc Am Soc Clin Oncol 2002; 21:277a (Abstract #1107).
19. Browman GP, Belch A, Skillings J, et al. Modified adriamycin-vincristine-dexamethasone (m-VAD) in primary refractory and relapsed plasma cell myeloma: an NCI (Canada) pilot study. The National Cancer Institute of Canada Clinical Trials Group. Br J Haematol 1992; 82:555-559.
20. Dimopoulos MA, Pouli A, Zervas K, et al. Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma. Ann Oncol 2003; 14:1039-1044.